Introducing TSI’s BioTrak™ Real-Time Viable Particle Counter
2 July 2012 | By TSI
The latest innovation in rapid microbiology method instrument technology is real-time viable detectors...
List view / Grid view
News
Bristol-Myers Squibb and AstraZeneca expand diabetes alliance through Bristol-Myers Squibb’s acquisition of Amylin Pharmaceuticals
30 June 2012 | By AstraZeneca
Bristol-Myers Squibb to acquire Amylin...
Avacta expands following Aptuscan acquisition
29 June 2012 | By kdm communications limited
Avacta Group has expanded its Yorkshire headquarters with the addition of new laboratory, office and manufacturing space...
Biogen Idec and Isis announce global collaboration for antisense program targeting myotonic dystrophy
29 June 2012 | By Biogen Idec
Isis expands its rare disease franchise to include DM1...
GSK sets 20 July for expiration of tender offer to acquire Human Genome Sciences
29 June 2012 | By GlaxoSmithKline
Expiration is after HGS process bid deadline of 16 July...
Marketing and manufacturing approval received for TENELIA(R) 20mg tablets
29 June 2012 | By Daiichi Sankyo
A DPP-4 Inhibitor for Type 2 Diabetes Mellitus Originating from Japan...
Syrris celebrates successful flow and automated process chemistry seminars
28 June 2012 | By kdm communications limited
Syrris’ latest free flow chemistry and automated process chemistry seminars, held during May in Dinslaken, Germany...
Gilead submits New Drug Application to U.S. FDA for boosting agent cobicistat
28 June 2012 | By Gilead Sciences
Gilead Sciences has submitted a New Drug Application to the U.S. FDA for marketing approval of cobicistat...
Two-year study in over 1,500 patients compares Trajenta® (linagliptin) to the commonly prescribed sulphonylurea glimepiride
28 June 2012 | By Boehringer Ingelheim
Results from a two-year study published in The Lancet today demonstrate that Trajenta® (linagliptin) provides similar blood glucose improvements when compared to the commonly prescribed sulphonylurea, glimepiride, in adult patients with type 2 diabetes (T2D) inadequately controlled on metformin alone. The publication also describes that linagliptin was associated with significantly…
New Phase 3 data show STELARA® significantly reduced signs and symptoms of active Psoriatic Arthritis
27 June 2012 | By Janssen Research & Development, LLC
Treatment also resulted in significant improvements in physical function...
Roche Nutley, NJ to close research and development activities
27 June 2012 | By Roche
Roche site in Nutley (New Jersey, USA) to be closed – respective R&D activities to be consolidated in Switzerland and Germany...
Gilead submits NDA to U.S. FDA for HIV integrase inhibitor elvitegravir for treatment-experienced patients
27 June 2012 | By Gilead Sciences Inc
Elvitegravir is also a component of Quad single tablet regimen...
Pharma Japan 2012: BASF presents its comprehensive and intelligent pharmaceutical solutions
27 June 2012 | By BASF
BASF showcases its comprehensive solution profile with solid expertise...
AstraZeneca and Merck agree to amend second option
27 June 2012 | By AstraZeneca
AstraZeneca and Merck have agreed to amend certain provisions of the agreements relating to the companies’ arrangements in the US...
Abbott, The Abbott Fund and Direct Relief International reach key HIV testing milestone
27 June 2012 | By Abbott
20 million tests provided over 10 years & more than 150,000 HIV cases prevented...
